Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea.
World J Surg. 2009 Dec;33(12):2688-94. doi: 10.1007/s00268-009-0248-3.
Performing a restaging work-up with magnetic resonance imaging (MRI) and (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)F-FDG PET/CT) can provide information about the effects that are related to preoperative concurrent chemoradiotherapy (CCRT). The purpose of the present study was to investigate the accuracy of MRI and (18)F-FDG PET/CT for restaging after preoperative CCRT for rectal cancer.
Between April 2005 and February 2006, 30 patients with histologically proven rectal adenocarcinoma were included in this study. Pelvic MRI and (18)F-FDG PET/CT were performed to clinically restage the tumor after CCRT. The results of the pathologic staging were correlated with those of the MRI and (18)F-FDG PET/CT after CCRT. Two patients underwent transanal endoscopic microsurgery after CCRT, and they were excluded when the N category was evaluated.
The overall accuracy of MRI for the T category was 67% (kappa = 0.422, P = 0.003), whereas overstaging and understaging occurred in 30 and 3% of the patients, respectively. For the N category, accurate staging was noted in 75% (kappa = 0.410, P = 0.030) of all the patients, whereas 14% were overstaged and 11% were understaged. The overall accuracy rates for the T and N categories with performing (18)F-FDG PET/CT were 60% (kappa = 0.372, P = 0.004) and 71% (kappa = 0.097, P = 0.549), respectively. While MRI could not predict any patient who showed a pathologic complete response, (18)F-FDG PET/CT predicted three of the four patients who showed a pathologic complete response after preoperative CCRT. Furthermore, (18)F-FDG PET/CT identified distant metastases with an accuracy rate of 97%.
For restaging patients with rectal cancer after preoperative CCRT, MRI is a useful diagnostic modality to predict both the T and N categories. (18)F-FDG PET/CT is helpful in predicting a pathologic complete response and in finding metastasis after preoperative CCRT.
使用磁共振成像(MRI)和(18)F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描((18)F-FDG PET/CT)进行重新分期可提供与术前同期放化疗(CCRT)相关的效果信息。本研究的目的是研究 MRI 和(18)F-FDG PET/CT 在术前 CCRT 后对直肠癌重新分期的准确性。
2005 年 4 月至 2006 年 2 月,纳入 30 例经组织学证实的直肠腺癌患者。在 CCRT 后进行盆腔 MRI 和(18)F-FDG PET/CT 以临床重新分期肿瘤。将病理分期结果与 CCRT 后的 MRI 和(18)F-FDG PET/CT 结果相关联。2 例患者在 CCRT 后接受经肛门内镜微创手术,在评估 N 分期时将其排除在外。
MRI 对 T 分期的总体准确性为 67%(kappa=0.422,P=0.003),分别有 30%和 3%的患者出现过度分期和分期不足。对于 N 分期,所有患者的准确分期率为 75%(kappa=0.410,P=0.030),14%的患者分期过度,11%的患者分期不足。进行(18)F-FDG PET/CT 时,T 期和 N 期的总准确率分别为 60%(kappa=0.372,P=0.004)和 71%(kappa=0.097,P=0.549)。虽然 MRI 不能预测任何表现为病理完全缓解的患者,但(18)F-FDG PET/CT 预测了 4 例术前 CCRT 后表现为病理完全缓解的患者中的 3 例。此外,(18)F-FDG PET/CT 对远处转移的准确率为 97%。
对于术前 CCRT 后直肠癌患者的重新分期,MRI 是一种有用的诊断方式,可预测 T 期和 N 期。(18)F-FDG PET/CT 有助于预测病理完全缓解和发现术前 CCRT 后的转移。